// App-Quantinova.ai

1339 : Preclinical combination activity of SGN-CD19A and CVAD in patient-derived B-lineage acute lymphoblastic leukemia models

Researchers

Presenter

  • Ivan J. Stone

Principal Investigators

  • Tina Albertson

  • Che-Leung Law

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Seattle Genetics, In

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

  • Apparent diffusion coefficient

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Vincristine

  • Doxorubicin

  • SGN-CD19A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved